Skip to main content
main-content

18-06-2021 | ASCO 2021 | Conference coverage | Video

Neoadjuvant talazoparib active in BRCA-mutated early breast cancer

Jennifer Litton discusses results of the NEOTALA trial suggesting patients with germline BRCA1/2-mutant, HER2-negative, early breast cancer may benefit from neoadjuvant treatment with talazoparib (4:56).

Read transcript

ESMO Congress 2021

Access our ongoing coverage including the latest news and expert video interviews.

Image Credits